Additional therapy for chronic heart diseases (heart failure, post-infarction period), heart rhythm disorders, especially ventricular arrhythmias, on the recommendation of a doctor. Additional therapy for treatment with digitalis drugs, on the recommendation of a doctor. As a Supplement to the diet to increase the levels of magnesium and potassium in the body.
Panangyn composition and form of release
It is made in the form of film-coated tablets and in solution for injection. The main ingredients of the drug are magnesium asparaginate and potassium asparaginate.
Panangyn is used in the complex treatment of acute myocardial infarction, heart failure and heart rhythm disturbances.
Also, the drug is prescribed in conjunction with cardiac glycosides to improve their tolerance, replenish the deficiency of magnesium and potassium, which are caused by an insufficient content of these elements in the patient’s diet.
It is unacceptable to use in the therapy of patients who have chronic or acute renal failure, hyperkalemia, Addison’s disease, cardiogenic shock, severe myasthenia gravis, amino acid metabolism disorders, acute metabolic acidosis, severe dehydration of the body and hypersensitivity to magnesium asparaginate or potassium asparaginate.
With caution, the administration of the drug is administered to patients in the first trimester of pregnancy and during lactation.
It is necessary to be extremely careful when prescribing the drug to patients who have degree I AV blockade, liver dysfunction, hypophosphatemia, metabolic acidosis, urolithiasis diathesis, and the risk of edema. The drug is not prescribed for patients with impaired renal function, if it is not possible to constantly monitor the level of magnesium in the blood.
When prescribing Panangyn, it must be remembered that its coadministration with diuretics, beta-blockers, heparin, cyclosporine and non-steroidal anti-inflammatory drugs significantly increases the patient’s risk of hyperkalemia, arrhythmia and asystole.
Application during pregnancy and lactation
There is no evidence that the drug can have a negative effect on the development of a fetus or child who is breastfed by a mother receiving this drug. However, despite the absence of a negative effect, the appointment of the drug for women at the stage of lactation and pregnancy is made only according to strict medical instructions.
Method of administration and dosage
Oral Panangyn is taken in 1 or 2 tablets 3 r / s. The drug is taken after a meal, as the acidic gastric environment reduces its therapeutic efficacy. The doctor chooses the duration of therapy individually.
To date, there have been no officially described cases of overdose. When taking the drug in high doses, the risk of developing hypermagnesemia or hyperkalemia significantly increases.
With hyperkalemia, the patient has increased fatigue, paresthesia, heart rhythm disturbances, myasthenia gravis, confusion.
Hypermagnesemia is characterized by a decrease in neuromuscular excitability, the occurrence of nausea, vomiting, lethargy, and a pronounced decrease in blood pressure. A sharp increase in the content of magnesium ions in the blood plasma can cause a sharp suppression of tendon reflexes, paralysis of the respiratory system and coma.
To stabilize the patient’s condition, it is necessary to urgently stop the administration of the drug and prescribe the correct symptomatic treatment to the patient. In especially severe cases, hemodialysis is indicated.
During therapy, it is possible to develop AV blockade and a paradoxical reaction, characterized by an increase in the number of extrasystoles. Also, when taking the drug inside, nausea, vomiting, stool disturbances, discomfort in the epigastric region, hyperkalemia and hypermagnesemia may occur.
Storage conditions and periods
Panangyn is stored in a dry, dark place out of the reach of children. Duration of storage of the drug is 5 years.